Plan Carefully In Writing Combo Product Designation Requests, Experts Say
This article was originally published in The Gray Sheet
Companies need to carefully consider tactics for ensuring proper regulation of combination products, including looking at whether a manufacturer really needs a formal request for designation, say industry and legal experts.
You may also be interested in...
FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.